Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage - Älteste Beiträge zuerst (Seite 108)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 14.05.24 09:48:52 von
neuester Beitrag 14.05.24 09:48:52 von
Beiträge: 23.060
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 466
Gesamt: 1.246.668
Gesamt: 1.246.668
Aktive User: 9
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVV1
12,850
EUR
+5,78 %
+0,702 EUR
Letzter Kurs 09:49:55 Tradegate
Neuigkeiten
05:10 Uhr · inv3st.de Anzeige |
13.05.24 · Der Aktionär TV  |
10.05.24 · dpa-AFX |
10.05.24 · dpa-AFX |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,5300 | +38,25 | |
| 0,9999 | +31,55 | |
| 0,6570 | +30,62 | |
| 4,9780 | +23,40 | |
| 2,3550 | +20,15 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5000 | -18,48 | |
| 4,1200 | -18,64 | |
| 0,5350 | -20,15 | |
| 0,9900 | -27,21 | |
| 0,6162 | -56,61 |
Feedback
Why Novavax Shares Rocketed Higher By Nearly 25% in June
http://www.fool.com/investing/general/2015/07/07/why-novavax…
http://www.fool.com/investing/general/2015/07/07/why-novavax…
Gaithersburg biotech expands into new research facility, preps for last phase of drug trials
Jun 4, 2015, 3:41pm EDT
...Novavax also said it has begun manufacturing a vaccine for potential Phase 3 clinical trials of its leading vaccine candidate for respiratory syncytial virus, or RSV. RSV is the most common cause of inflammation of the small airways in the lung and pneumonia in children under 1 in the U.S., but impacts other age groups as well. Novavax has been in the midst of Phase 2 trials of its RSV vaccine in pregnant women and for elderly patients.
http://www.bizjournals.com/washington/blog/2015/06/gaithersb…
Jun 4, 2015, 3:41pm EDT
...Novavax also said it has begun manufacturing a vaccine for potential Phase 3 clinical trials of its leading vaccine candidate for respiratory syncytial virus, or RSV. RSV is the most common cause of inflammation of the small airways in the lung and pneumonia in children under 1 in the U.S., but impacts other age groups as well. Novavax has been in the midst of Phase 2 trials of its RSV vaccine in pregnant women and for elderly patients.
http://www.bizjournals.com/washington/blog/2015/06/gaithersb…
Citigroup Inc. Increases Novavax Price Target to $18.00 (NVAX)
Posted on July 9, 2015 by Justin Garson in Analyst Articles - US, Investing
Equities research analysts at Citigroup Inc. raised their target price on shares of Novavax (NASDAQ:NVAX) from $10.00 to $18.00 in a research note issued to investors on Thursday, AnalystRatings.Net reports. Citigroup Inc.’s price objective would suggest a potential upside of 64.99% from the company’s current price.
http://sleekmoney.com/citigroup-inc-increases-novavax-price-…
Posted on July 9, 2015 by Justin Garson in Analyst Articles - US, Investing
Equities research analysts at Citigroup Inc. raised their target price on shares of Novavax (NASDAQ:NVAX) from $10.00 to $18.00 in a research note issued to investors on Thursday, AnalystRatings.Net reports. Citigroup Inc.’s price objective would suggest a potential upside of 64.99% from the company’s current price.
http://sleekmoney.com/citigroup-inc-increases-novavax-price-…
Die Homepage bekam eine Auffrischung und Gail Boudreaux steigt mit ins Boot. Meiner Meinung nach sind das nicht unbedingt Zeichen für schlechte Ergebnisse.
gabs hierzu ne Meldung?
BARDA Contract
...In June 2015, the contract was increased by $7.7 million to allow for the recovery of additional costs under the contract relating to the settlement of indirect rates for fiscal years 2011 and 2012. This additional amount was recorded as revenue in the three months ended June 30, 2015 and payment was received in July 2015.
http://novavax.com/page/16/barda-contract
gabs hierzu ne Meldung?
BARDA Contract
...In June 2015, the contract was increased by $7.7 million to allow for the recovery of additional costs under the contract relating to the settlement of indirect rates for fiscal years 2011 and 2012. This additional amount was recorded as revenue in the three months ended June 30, 2015 and payment was received in July 2015.
http://novavax.com/page/16/barda-contract
Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference
GAITHERSBURG, Md., July 21, 2015 (GLOBE NEWSWIRE)
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™ as part of the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax’ proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing.
The Ebola GP Vaccine clinical trial is a randomized, observer-blinded, dose-escalation trial to evaluate the safety and immunogenicity of the vaccine, with and without Matrix-M, in 230 healthy adults between 18 and 49 years of age. Participants received either one or two intramuscular injections ranging from 6.5µg to 50µg of antigen on study days 0 and 21. Immunogenicity was assessed at multiple time points including days 28 and 35.
The adjuvanted Ebola GP Vaccine was highly immunogenic at all dose levels. The adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000 ELISA units (GMEU), representing a 500 to 750-fold rise over baseline at day 35. The adjuvanted single dose vaccine regimen induced GMEU between 1700 and 3400, representing a 21 to 27-fold rise over baseline at day 35.
“We are pleased to have the opportunity to share these positive data with the WHO. Novavax’ recombinant nanoparticle technology and proprietary Matrix-M adjuvant differentiates our Ebola GP Vaccine. The Phase 1 clinical data show that our vaccine was well-tolerated and elicited very high Ebola antibody responses,” said Gregory Glenn, M.D., Senior Vice President, Research and Development. “These data, together with two positive challenge studies in non-human primates, suggest that the Ebola GP Vaccine would be protective in humans.”
Stanley C. Erck, President and CEO said, “These positive data represent the third time Novavax has leveraged the power of our platform technology to rapidly address an emerging threat. These Ebola GP Vaccine data, in combination with clinical data from our H7N9 VLP vaccine candidate and preclinical data from our vaccine candidate for Middle East Respiratory Syndrome coronavirus, provide additional validation of our nanoparticle vaccine platform. Our Ebola GP Vaccine, adjuvanted with Matrix-M, was highly immunogenic at low doses, allowing for dose-sparing. Further, our recombinant vaccines do not need to be shipped or stored frozen, a key consideration for a vaccine developed against a novel lethal virus with pandemic potential.”
Today’s Novavax presentation to the WHO can be accessed via the Presentations section of the Novavax website, www.novavax.com by close of business today.
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
GAITHERSBURG, Md., July 21, 2015 (GLOBE NEWSWIRE)
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™ as part of the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax’ proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing.
The Ebola GP Vaccine clinical trial is a randomized, observer-blinded, dose-escalation trial to evaluate the safety and immunogenicity of the vaccine, with and without Matrix-M, in 230 healthy adults between 18 and 49 years of age. Participants received either one or two intramuscular injections ranging from 6.5µg to 50µg of antigen on study days 0 and 21. Immunogenicity was assessed at multiple time points including days 28 and 35.
The adjuvanted Ebola GP Vaccine was highly immunogenic at all dose levels. The adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000 ELISA units (GMEU), representing a 500 to 750-fold rise over baseline at day 35. The adjuvanted single dose vaccine regimen induced GMEU between 1700 and 3400, representing a 21 to 27-fold rise over baseline at day 35.
“We are pleased to have the opportunity to share these positive data with the WHO. Novavax’ recombinant nanoparticle technology and proprietary Matrix-M adjuvant differentiates our Ebola GP Vaccine. The Phase 1 clinical data show that our vaccine was well-tolerated and elicited very high Ebola antibody responses,” said Gregory Glenn, M.D., Senior Vice President, Research and Development. “These data, together with two positive challenge studies in non-human primates, suggest that the Ebola GP Vaccine would be protective in humans.”
Stanley C. Erck, President and CEO said, “These positive data represent the third time Novavax has leveraged the power of our platform technology to rapidly address an emerging threat. These Ebola GP Vaccine data, in combination with clinical data from our H7N9 VLP vaccine candidate and preclinical data from our vaccine candidate for Middle East Respiratory Syndrome coronavirus, provide additional validation of our nanoparticle vaccine platform. Our Ebola GP Vaccine, adjuvanted with Matrix-M, was highly immunogenic at low doses, allowing for dose-sparing. Further, our recombinant vaccines do not need to be shipped or stored frozen, a key consideration for a vaccine developed against a novel lethal virus with pandemic potential.”
Today’s Novavax presentation to the WHO can be accessed via the Presentations section of the Novavax website, www.novavax.com by close of business today.
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
Trading Spotlight
•Novavax Ebola/Makona Glycoprotein (GP) Nanoparticle Vaccine Candidate Update: NHP and Clinical Data
July 21, 2015
...Pending, ~ 24 July, neutralization data on same 100 serum panel from University of Marburg (Dr. Becker)
http://novavax.com/download/files/presentations/Novavax_EBOV…
July 21, 2015
...Pending, ~ 24 July, neutralization data on same 100 serum panel from University of Marburg (Dr. Becker)
http://novavax.com/download/files/presentations/Novavax_EBOV…
Heisse Aktie im Moment. Insbesondere interessant für Call-Schreiber Strategien (aufgrund der hohen Vola). I like that stock.
http://cnb.cx/1IeITwU
http://cnb.cx/1IeITwU
Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP
GAITHERSBURG, Md., July 30, 2015 (GLOBE NEWSWIRE)
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
GAITHERSBURG, Md., July 30, 2015 (GLOBE NEWSWIRE)
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
Novavax Reports Second Quarter 2015 Financial Results
GAITHERSBURG, Md., Aug. 10, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults
GAITHERSBURG, Md., Aug. 10, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
GAITHERSBURG, Md., Aug. 10, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults
GAITHERSBURG, Md., Aug. 10, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization
Bill & Melinda Gates Foundation to Support Development of the RSV F Vaccine Program
GAITHERSBURG, Md., Sept. 29, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization
-RSV F Vaccine was safe and well-tolerated
-Significant anti-F, PCA and microneutralizing antibody responses elicited in mothers
-Efficient antibody transfer from mothers to infants observed
-Results suggest potential to protect infants when they are most at risk
GAITHERSBURG, Md., Sept. 29, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
Bill & Melinda Gates Foundation to Support Development of the RSV F Vaccine Program
GAITHERSBURG, Md., Sept. 29, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization
-RSV F Vaccine was safe and well-tolerated
-Significant anti-F, PCA and microneutralizing antibody responses elicited in mothers
-Efficient antibody transfer from mothers to infants observed
-Results suggest potential to protect infants when they are most at risk
GAITHERSBURG, Md., Sept. 29, 2015
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArtic…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,07 | |
| +0,02 | |
| +0,15 | |
| +0,57 | |
| +0,68 | |
| +0,28 | |
| +0,19 | |
| -0,26 | |
| -0,23 | |
| +0,58 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 165 | ||
| 78 | ||
| 73 | ||
| 70 | ||
| 65 | ||
| 53 | ||
| 52 | ||
| 45 | ||
| 38 | ||
| 36 |
Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage
